ArticleDiabetes2013
GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes.
Article in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Expression-Based Genome-Wide Association Study Links Vitamin D-Binding Protein With Autoantigenicity in Type 1 Diabetes.Diabetes · 2016Pooled it
- Single Autoantibody Positivity in Pediatric Type 1 Diabetes: Serological Profiles, Clinical Trajectories and Implications for Early Disease Monitoring-A Case Series of Seven Patients.Life (Basel, Switzerland) · 2026Article
- Differential Contributions of IgM and IgG Autoantibodies to Serologic IA2 Reactivity in Type 1 Diabetes.Biomolecules · 2026Article
- Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA.Diabetes · 2026Article
- Early Detection of Pediatric Type 1 Diabetes: The Expanding Role of Screening.Children (Basel, Switzerland) · 2026Review
- Molecular Portrait of Autoantigens in Type 1 Diabetes.Biomolecules · 2025Review
- Prevalence of Islet Autoantibodies in Adults Without Diabetes.Journal of the Endocrine Society · 2025Article
- Article
- Prediction of future insulin-deficiency in glutamic acid decarboxylase autoantibody enzyme-linked immunosorbent assay-positive patients with slowly-progressive type 1 diabetes.Journal of diabetes investigation · 2024Article
- Improved Specificity of Glutamate Decarboxylase 65 Autoantibody Measurement Using Luciferase-Based Immunoprecipitation System Assays.Diabetes · 2024Article
- Decoding the relationship between cow's milk proteins and development of type 1 diabetes mellitus.Archives of endocrinology and metabolism · 2024Article
- Understanding Islet Autoantibodies in Prediction of Type 1 Diabetes.Journal of the Endocrine Society · 2023Review
- Prevalence of antibodies targeting ubiquitin-conjugating enzyme 2L3 and eukaryote translation elongation factor 1 α1 in Chinese Han and American Caucasian populations with type 1 diabetes.Endocrine connections · 2022Article
- A High-throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19.Journal of visualized experiments : JoVE · 2022Article
- High-Throughput Multiplex Electrochemiluminescence Assay Applicable to General Population Screening for Type 1 Diabetes and Celiac Disease.Diabetes technology & therapeutics · 2022Article
- Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes.The Journal of clinical endocrinology and metabolism · 2022Article
- Article
- Effective assay technologies fit for large-scale population screening of type 1 diabetes.Frontiers in clinical diabetes and healthcare · 2022Review
- High-affinity ZnT8 Autoantibodies by Electrochemiluminescence Assay Improve Risk Prediction for Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2021Article
- Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes.Diabetologia · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The identification of diabetes-relevant islet autoantibodies is essential for predicting and preventing type 1 diabetes (T1D). The aim of the current study was to evaluate a newly developed electrochemiluminescence (ECL)-GAD antibody (GADA) assay and compare its sensitivity and disease relevance with standard radioassay. The assay was validated with serum samples from 227 newly diagnosed diabetic children; 68 prediabetic children who were prospectively followed to T1D; 130 nondiabetic children with confirmed islet autoantibodies to insulin, GAD65, IA-2, and/or ZnT8 longitudinally followed for 12 ± 3.7 years; and 181 age-matched, healthy, antibody-negative children. The ECL-GADA assay had a sensitivity similar to that of the standard GADA radioassay in children newly diagnosed with T1D, prediabetic children, and high-risk children with multiple positive islet autoantibodies. On the other hand, only 9 of 39 nondiabetic children with only a single islet autoantibody (GADA only) by radioassay were positive for ECL-GADA. GADA not detectable by ECL assay is shown to be of low affinity and likely not predictive of future diabetes. In conclusion, the new ECL assay identifies disease-relevant GADA by radioassay. It may help to improve the prediction and correct diagnosis of T1D among subjects positive only for GADA and no other islet autoantibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.